Hadia Farrukh

Hadia Farrukh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HFHadia Farrukh
Hadia Farrukh
NENader El-Sayes
Nader El-Sayes
Karen MossmanKaren Mossman
Karen Mossman
Programmed cell death protein 1 (PD-1), a receptor on T cells, and its ligand, PD-L1, have been a topic of much interest in cancer research. Both tumour and virus-infected cells can upregulate PD-L1 to suppress cytotoxic T-cell killing. Research on the PD-1/PD-L1 axis has led to the development of anti-PD-1/PD-L1 immune checkpoint blockades (ICBs) as promising cancer therapies. Although effective in some cancer patients, for many, this form of treatment is ineffective due to a lack of immunogenicity in the tumour microenvironment (TME). Despite the development of therapies targeting the PD-1/PD-L1 axis, the mechanisms and pathways through which these proteins are regulated are not completely understood. In this review, we discuss the latest research on molecules of inflammation and innate immunity that regulate PD-L1 expression, how its expression is regulated during viral infection, and how it is modulated by different cancer therapies. We also highlight existing research on the development of different combination therapies with anti-PD-1/PD-L1 antibodies. This information can be used to develop better cancer immunotherapies that take into consideration the pathways involved in the PD-1/PD-L1 axis, so these molecules do not reduce their efficacy, which is currently seen with some cancer therapies. This review will also assist in understanding how the TME changes during treatment, which will provide further rationale for combination therapies.

30 May 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
HFHadia Farrukh
Hadia Farrukh
AKAbbey Michelle Kunzli
Abbey Michelle Kunzli
OVOlivia Virag
Olivia Virag
NONathan O’hara
Nathan O’hara
SSSheila Sprague
Sheila Sprague
MGMichelle Ghert
Michelle Ghert
The proximal femur represents the most frequent site in the appendicular skeleton for metastatic bone disease (MBD) to occur, with a high risk for pathologic fracture. While surgical stabilization is typically used to manage fractures, reconstruction approaches are gaining popularity due to improved survival. Previous studies have focused on clinical outcomes, but patient-centered outcomes remain underexplored. This study aims to develop a patient-centered primary outcome for the Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Randomized Controlled Trial, employing a mixed-methods approach. First, a focus group with advanced cancer patients and caregivers identified relevant outcomes. Next, a discrete choice experiment (DCE) assessed the importance of these outcomes among stakeholders, including surgeons, patients and caregivers. The most important components for the primary outcome were identified: mortality within twelve months, physical function assessed at four months using the PROMIS® Global Physical Function score, and the number of days at home within twelve months. The DCE further confirmed that survival and physical function were most prioritized. The PERFORM trial’s primary outcome, developed through extensive stakeholder engagement, will guide the evaluation of surgical approaches for MBD of the proximal femur and has the potential to influence patient-centered practice.

4 December 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
HFHadia Farrukh
Hadia Farrukh
PSPatricia Schneider
Patricia Schneider
THTess Hudson
Tess Hudson
VGVictoria Giglio
Victoria Giglio
RBRicardo Becker
Ricardo Becker
MGMichelle Ghert
Michelle Ghert
Soft-tissue sarcomas (STSs) are rare malignancies predominantly found in the extremities. Surgery and radiation are standard treatments, but post-operative pulmonary surveillance, involving clinical visits and thoracic imaging, is crucial due to a high recurrence rate, most commonly to the lungs. Current pulmonary surveillance guidelines lack robust evidence. The Surveillance AFter Extremity Tumor SurgerY (SAFETY) randomized controlled trial is designed to determine the impact of pulmonary surveillance frequency (every three versus six months) and chest imaging modality (CXR versus CT) on patient-important outcomes. The pilot phase assessed feasibility of patient enrolment, protocol adherence, and data quality, as well as aggregate outcomes at two years of follow-up. 100 patients were enrolled from 300 screened patients across 17 international sites. Minor protocol deviations were common. Follow-up, data completeness and data quality met the progression criteria of 85%. Of the 100 patients, 15 died, 21 had metastases, seven had local recurrence and 30 experienced at least one serious adverse event. This SAFETY trial study established feasibility of enrolment and data quality, and confirmed the need to emphasize protocol adherence in sarcoma care. The results of this trial are expected to provide crucial evidence to standardize STS pulmonary surveillance practices, ultimately improving patient management and expectations.

6 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SUSerena Uppal
Serena Uppal
MGMichelle Ghert
Michelle Ghert
HFHadia Farrukh
Hadia Farrukh
TIthe PARITY Investigators
the PARITY Investigators
Background Research study protocols are critical in study design, however study implementation can be subject to protocol deviations. The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial assessed prophylactic intravenous antibiotics on the rate of surgical site infection in patients undergoing oncological endoprosthetic reconstruction of the lower extremity. The objective of this study was to identify the protocol deviations – missed antibiotic doses – in the PARITY trial, and determine the causes of the protocol deviations. Methods This study is a secondary analysis of the PARITY trial data set. The patients in the original trial were randomized to receive either 24 hours or five days of postoperative intravenous antibiotics, for a total of 15 doses. Patients that missed doses and the reason for each missed dose were recorded in the database and summarized descriptively herein. This data was then compared between clinical sites with high and low volume, between nationalities and between the economic development status of the clinical site location. Results The PARITY trial included 604 participants with 218 patients missing at least one antibiotic dose. The most common reason across all clinical sites was that patients were discharged earlier than the five-day protocol. This finding was consistent across high and low volume sites and across clinical sites in areas of different economic development. The reasons for protocol deviations varied across clinical sites of different nationalities. Conclusions Protocol deviations – missed antibiotic doses – were common but of minimal severity in the PARITY trial. The most commonly reported reason for missed antibiotic doses was discharge earlier than the five-day protocol and not due to clinical site personnel error. Nevertheless, this study did identify actionable improvements to study protocol adherence such as careful monitoring of drug administration, investigator equipment, and availability of study drug.